Literature DB >> 9317165

HIV-1 reverse transcriptase-specific CTL against conserved epitopes do not protect against progression to AIDS.

S H van der Burg1, M R Klein, O Pontesilli, A M Holwerda, J W Drijfhout, W M Kast, F Miedema, C J Melief.   

Abstract

A small group of HIV-1-infected subjects who either do not progress to AIDS or progress only slowly have sustained HIV-1-specific CTL responses. It has been suggested that the specificities of these responses differ from the CTL responses of rapid progressors due to recognition of epitopes that are under structural or functional constraints. We have, in this respect, studied the CTL response to reverse transcriptase (RT) in long term survivors (LTS) and in HIV-1-infected individuals who progressed to AIDS within 3 to 6 yr. Both LTS and progressors displayed vigorous RT-specific CTL responses of comparable magnitude during the asymptomatic phase. From each individual at least two CTL lines were obtained from blood samples drawn at different time points during follow-up. A total of 19 CTL lines recognized nine different RT-derived epitopes. CTL obtained from progressors recognized epitopes with a similar degree of amino acid conservation as epitopes targeted by CTL from LTS. Furthermore, five of seven epitopes were recognized by both LTS and progressors. Moreover, one of the epitopes recognized by progressors contained the highly conserved YMDD motif that is essential for RT activity. In conclusion, our data imply that neither the magnitude nor the specificity of HIV-1-specific CTL against RT is a major cause of a more protracted course of disease.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9317165

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  Immunogenicity of mutations induced by nucleoside reverse transcriptase inhibitors for human immunodeficiency virus type 1-specific cytotoxic T cells.

Authors:  A Samri; G Haas; J Duntze; J M Bouley; V Calvez; C Katlama; B Autran
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

2.  Sequence analysis of the polymerase domain of HIV-1 reverse transcriptase in naive and zidovudine-treated individuals reveals a higher polymorphism in alpha-helices as compared with beta-strands.

Authors:  L Medrano; L Menéndez-Arias; R De Jorge; M L Villahermosa; G Contreras; L Pérez-Alvarez; A Moya; R Nájera
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

3.  Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.

Authors:  Nozomi Kuse; Mohammad Arif Rahman; Hayato Murakoshi; Giang Van Tran; Takayuki Chikata; Madoka Koyanagi; Kinh Van Nguyen; Hiroyuki Gatanaga; Shinichi Oka; Masafumi Takiguchi
Journal:  J Virol       Date:  2015-05-13       Impact factor: 5.103

4.  Vpu increases susceptibility of human immunodeficiency virus type 1-infected cells to fas killing.

Authors:  C R Casella; E L Rapaport; T H Finkel
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

5.  Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro.

Authors:  C A Van Baalen; M Schutten; R C Huisman; P H Boers; R A Gruters; A D Osterhaus
Journal:  J Virol       Date:  1998-08       Impact factor: 5.103

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.